{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061519","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.893847+00:00","generated_at":"2026-06-08T07:34:32.855632+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ikena reports Q3 cash $196.9M, IK-930 shows stable disease in all 7 EHE patients","bullets":["Q3 2023 cash, cash equivalents and marketable securities of $196.9M; runway into 2026.","IK-930 dose escalation: 26 patients treated; 7/7 EHE patients achieved stable disease, 3 with tumor shrinkage.","Treatment-related proteinuria in 3/26 patients, all grade 1-2, no dose reductions or interruptions.","IK-595 clinical trial expected to initiate by end of 2023; IK-930 data update planned for H2 2024.","Collaboration revenue $1.2M vs $6.4M YoY; R&D expenses $14.7M vs $18.9M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061519","json":"https://secwatch.observer/filing/0000950170-23-061519.json","markdown":"https://secwatch.observer/filing/0000950170-23-061519.md","text":"https://secwatch.observer/filing/0000950170-23-061519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/0000950170-23-061519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/ikna-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:34:32.855632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f107c463daece9609f0ca6461c752f722264169c","claim":"ImageneBio, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Ikena Oncology, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/0000950170-23-061519-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}